Tilray Medical Launches in Italy, Strengthening Cannabis Operations in Europe
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Source: seekingalpha
- Brand Transformation: Tilray Medical rebrands FL Group to Tilray Medical Italia, aiming to enhance its market position in Europe through a unified medical cannabis platform, particularly in the key regulated market of Italy.
- Product Expansion: Tilray Medical Italia is expanding its footprint in Italy by launching a portfolio of medical cannabis products authorized by the Italian Ministry of Health, supported by a partnership with Molteni Farmaceutici.
- International Growth Outlook: Tilray anticipates a global medical cannabis revenue run rate of $150 million by 2026, indicating that its international expansion strategy is accelerating and further solidifying its competitive edge in the global market.
- Quarterly Revenue Surge: Tilray reported record quarterly revenue in its latest earnings report, primarily driven by growth in medical cannabis sales, showcasing the company's strong performance in the rapidly evolving medical cannabis sector.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 8.730
Low
8.50
Averages
9.57
High
10.00
Current: 8.730
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
